This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Drugs

Will This New Rating Help Pfizer (PFE) Stock Today?

Will This New Rating Help Pfizer (PFE) Stock Today?

  • Tickers in this article:
  • PFE

Deutsche Bank starts coverage of Pfizer (PFE) with a 'buy' rating and a $34 price target.

08/27/14 - 09:09 AM EDT

Previewing Tetraphase Oral Antibiotic Study Results

  • Tickers in this article:
  • TTPH

Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.

08/27/14 - 08:00 AM EDT

Try Jim Cramer's Action Alerts PLUS
Your September Biotech Back-to-School Calendar

Your September Biotech Back-to-School Calendar

The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.

08/26/14 - 09:50 AM EDT

Cramer: Behind Roche's InterMune Deal

Cramer: Behind Roche's InterMune Deal

  • Tickers in this article:
  • ITMN

The acquisition is a symbol of a much bigger trend.

08/25/14 - 11:41 AM EDT

European Stocks Rise After ECB President Draghi Signals Central Bankers Ready to Act

European stocks rose Monday after European Central Bank President Mario Draghi signaled that central bankers are prepared to tweak monetary policy if needed.

08/25/14 - 07:33 AM EDT

Aug. 25 Premarket Briefing: 10 Things You Should Know

Aug. 25 Premarket Briefing: 10 Things You Should Know

U.S. stock futures rise; Burger King in talks to buy Canada's Tim Hortons; Roche to buy InterMune for $8.3 billion; Sony's PlayStation hit with cyber-attack.

08/25/14 - 06:45 AM EDT

Intel, Home Depot, Microsoft Lead DJIA During Earnings Season

Intel, Home Depot, Microsoft Lead DJIA During Earnings Season

On Thursday, Home Depot became the last Dow component to report quarterly results. Here's how the 30 stocks in the DJIA fared during earnings season.

08/22/14 - 09:00 AM EDT

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech Stock Mailbag: Threshold, Galena, CytRx

Biotech columnist Adam Feuerstein answers readers' questions about health care.

08/22/14 - 08:48 AM EDT

Ampio: The Freezer Killed My Osteoarthritis Drug

Ampio: The Freezer Killed My Osteoarthritis Drug

  • Tickers in this article:
  • AMPE

Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.

08/21/14 - 10:23 AM EDT

Epizyme First Look at Blood Cancer Drug Encourages

Epizyme First Look at Blood Cancer Drug Encourages

  • Tickers in this article:
  • EPZM

Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.

08/21/14 - 08:59 AM EDT

Galena CEO Fired Following Stock-Promotions Scandal

Galena CEO Fired Following Stock-Promotions Scandal

  • Tickers in this article:
  • GALE

Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.

08/21/14 - 07:16 AM EDT

Yes, Call It a Comeback: Amicus Fabry Drug Posts Big Study Win

Yes, Call It a Comeback: Amicus Fabry Drug Posts Big Study Win

Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.

08/20/14 - 06:01 AM EDT

Is Now the Time to Buy Rite Aid Stock, or Should You Hold Off?

Is Now the Time to Buy Rite Aid Stock, or Should You Hold Off?

Is Rite Aid a buy right now or are Walgreens and CVS Caremark a better investment?

08/19/14 - 02:13 PM EDT

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

Why Spectrum Fell on Beleodaq Approval but Will Rocket on Melphalan Approval

  • Tickers in this article:
  • SPPI

Spectrum's Beleodaq for Non-Hodgkin's lymphoma received FDA approval on July 3, but the stock then fell 26%. The same thing won't happen with Melphalan because sales numbers are already established.

08/18/14 - 07:47 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs